Skip to main content
. Author manuscript; available in PMC: 2018 Jun 1.
Published in final edited form as: Biochim Biophys Acta. 2017 Mar 27;1862(6):636–645. doi: 10.1016/j.bbalip.2017.03.010

Figure 2. Circulating lipidomic profile in diabetes is dominated by cytochrome P 450 (CYP) /sEH pathway derived metabolites rather than 12/15-LO metabolites.

Figure 2

A) The activity of circulating 12/15-LO was not altered during diabetes as indicated by no significant changes in the plasma levels of major metabolites derived from 12/15-lipoxygenation of different PUFAs, including LA (9- and 13-HODEs), AA (12- and 15- HETEs), EPA (12- and 15- HEPEs), or DHA (14- and 17-HDoHE). B) In contrast to 12/15-LO metabolites, levels of CYP/sEH metabolites derived from different PUFAs showed an increasing trend in diabetes. This trend was significantly evident among 9,10-DiHOME, 5,6-DiHETrE, 11,12-DiHETrE, 14,15-DiHETrE. Data shown for the comparison are from the same experimental groups used in figure 1 and represented here by the mean fold change of 6 diabetic mice relative to the average of 8 nondiabetic mice ± SD.